Cell-Based Screening Platform

New studies demonstrate the ability of a new cell-based screening platform to produce unbiased, highly quantitative assays of migration and contraction of living cells, solving major problems that have limited the use of cell-based screening in drug discovery. The data from the studies were presented at the annual meeting of the American Society for Cell Biology in San Francisco (CA, USA).

This new platform, called Visible Discovery, was developed by Reify Corp. (Cambridge, MA, USA). The company has combined advanced machine learning and signal processing technologies with proprietary informatics to analyze complex cellular functions in high-throughput, continuously, and over time. This represents a critical breakthrough for drug discovery researchers, says Reify, who are increasingly turning to cell-based assays for earlier and more-accurate assessments of the efficacy and toxicity of candidate compounds.

"Where others have feared that dynamic living systems are too complex to be analyzed using automated high-throughput methods, we have embraced that complexity and are now beginning to use the rich phenotypic insights produced by Visible Discovery to fully automate the analysis and measurement of complex functions in living cells and model systems,” said Andrew Hack, M.D., Ph.D.




Related Links:
Reify Corp.